The Scleroderma Clinical Trial Consortium advances standards of research for people with scleroderma by conducting, sponsoring, and facilitating projects that improve clinical outcomes with a special focus on clinical trials.

Detailed Version:
The SCTC is an international consortium representing the majority of researchers and clinicians who have particular interest and expertise in the care of, and research in, scleroderma (systemic sclerosis).  The goal of the SCTC is to conduct, sponsor, or facilitate clinical research projects that lead to advances in the management, treatment, and outcomes of patients with scleroderma.  The SCTC represents the views and interests of its membership regarding the performance of clinical research in scleroderma.  The SCTC seeks to ensure that research in scleroderma adheres to high standards for design, conduct, and reporting of results.  The SCTC is particularly focused on improving and developing outcome measures for clinical trials and observational studies, participating in the design and conduct of clinical trials and observational studies, and helping to improve the efficiency of clinical trials.  The SCTC strongly encourages international collaboration, inclusiveness in research groups, and involvement of trainees and junior faculty in all its activities.

Congratulations to the Betty Z. Benedict Grant winners of 2022!
Dinesh Khanna and Alain Lescoat
This grant is co-sponsored by the Scleroderma Research Foundation.

Congratulations to the SCTC 2023 Working Group Grant Winners!